J. Grosso

发表

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

C. Drake, P. Hwu, A. Korman, 2012, The New England journal of medicine.

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

D. Getnet, C. Drake, G. Netto, 2009, Cancer research.

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

M. Millenson, M. Shipp, M. Dhodapkar, 2014 .

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

David C. Smith, A. Drilon, J. Wolchok, 2019, JAMA oncology.

A Unique Mucin Immunoenhancing Peptide with Antitumor Properties

T. Fu, D. Wreschner, J. Grosso, 2004, Cancer Research.

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

T. Yau, B. Sangro, T. Crocenzi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells 1

D. Getnet, C. Drake, D. Pardoll, 2009, The Journal of Immunology.

MUC1/sec-Expressing Tumors Are Rejected In Vivo by a T Cell-Dependent Mechanism and Secrete High Levels of CCL21

J. Grosso, L. Herbert, D. Lopez, 2004, The Journal of Immunology.

Radiotherapy augments the immune response to prostate cancer in a time‐dependent manner

D. Getnet, C. Drake, T. DeWeese, 2008, The Prostate.

A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression

C. Drake, A. Schaeffer, E. Schaeffer, 2015, The Journal of pathology.

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Clive R. Taylor, J. Taube, C. Horak, 2013 .

Programmed death-ligand 1 (PD-L1) expression in various tumor types

Xiaoling Zhang, J. Cogswell, J. Grosso, 2013, Journal of Immunotherapy for Cancer.

A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.

D. Getnet, C. Drake, D. Pardoll, 2010, Molecular immunology.

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

D. Getnet, C. Drake, Lieping Chen, 2007, Blood.

Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.

D. Getnet, C. Drake, A. D. De Marzo, 2013, International journal of radiation oncology, biology, physics.

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

J. Taube, C. Horak, J. Wolchok, 2014, Journal of Translational Medicine.

Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.

T. Cloughesy, D. Hafler, A. Omuro, 2015 .

Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues

P. Sorensen, J. Maris, B. Geoerger, 2017, Cancer.

Eos Mediates Foxp3-Dependent Gene Silencing in CD4+ Regulatory T Cells

Michael C. Ostrowski, Jun O. Liu, D. Getnet, 2009, Science.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

M. Millenson, M. Shipp, G. Freeman, 2015, The New England journal of medicine.

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1

D. Getnet, C. Drake, D. Pardoll, 2009, The Journal of Immunology.

Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Peter Vogel, Matthew P Smeltzer, David M Gravano, 2022 .

The expression of CCL2 by T lymphocytes of mammary tumor bearers: role of tumor-derived factors.

M. Torroella-Kouri, J. Grosso, L. Herbert, 2005, Cellular immunology.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

M. Millenson, M. Shipp, G. Freeman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

D. Getnet, C. Drake, A. D. De Marzo, 2007, The Journal of clinical investigation.

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

M. Jure-Kunkel, J. Grosso, Joseph F Grosso, 2013, Cancer immunity.

Up-Regulation of Matrix Metalloproteinase-9 in T Lymphocytes of Mammary Tumor Bearers: Role of Vascular Endothelial Growth Factor 1

J. Grosso, L. Herbert, D. Lopez, 2003, The Journal of Immunology.

Role of Vascular Endothelial Growth Factor T Lymphocytes of Mammary Tumor Bearers : Up-Regulation of Matrix Metalloproteinase-9 in

J. Grosso, L. Herbert, D. Lopez, 2003 .

Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity1

D. Getnet, C. Drake, D. Pardoll, 2009, The Journal of Immunology.

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

Christopher M. Jackson, D. Getnet, C. Drake, 2013, Journal of Translational Medicine.

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

A. Korman, S. Dillon, M. Selby, 2017, Oncoimmunology.

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

J. Taube, C. Horak, J. Wolchok, 2014, Journal of Translational Medicine.

Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1

Hua Yu, Drew M. Pardoll, Charles G. Drake, 2007, The Journal of Immunology.

Microenvironment and Immunology Immune InhibitoryMolecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

C. Liu, C. Drake, G. Netto, 2012 .

Stimulated CD8 T Cells Subsets on Activated and Chronically Functionally Distinct LAG-3 and PD-1

D. Getnet, D. Pardoll, D. Vignali, 2009 .

Current immunotherapeutic strategies in prostate cancer.

C. Drake, J. Grosso, 2007, Surgical oncology clinics of North America.

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

M. Millenson, M. Shipp, A. Ligon, 2014 .

Tc 17 CD 8 T Cells : Functional Plasticity and Subset Diversity 1

D. Getnet, C. Drake, D. Pardoll, 2017 .

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

C. Horak, J. Wolchok, M. Sznol, 2013 .

Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models.

A. Korman, S. Dillon, M. Selby, 2013 .

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

P. Ascierto, P. Ott, M. Pietanza, 2015 .

Up-Regulation of Matrix Metalloproteinase-9 in T Lymphocytes of Mammary Tumor Bearers: Role of Vascular Endothelial Growth Factor 1

J. Grosso, L. Herbert, D. Lopez, 2003, The Journal of Immunology.

Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.

C. Drake, J. Wigginton, L. Chow, 2013 .

Anti‐tumor effects of endogenous prostate cancer‐specific CD8 T cells in a murine TCR transgenic model

D. Getnet, C. Drake, G. Netto, 2012, The Prostate.

This information is current as Subset Diversity Tc 17 CD 8 T Cells : Functional Plasticity and

D. Getnet, D. Pardoll, S. Harris, 2009 .